Skip to Main Content

Hello, everyone, and how are you today? A warm and shiny sun is enveloping the Pharmalot campus this morning, where things have quieted down now that the shortest of short people has left for the schoolhouse and the official mascots are happily snoozing in their recliners. As for us, we are busy foraging for interesting items and, of course, quaffing some cups of stimulation. Feel free to join in. Meanwhile, here is the latest menu of tidbits. We hope you have a grand day or, at least, survive. And if you do, by all means, keep in touch…

After the New England Compounding Center shipped thousands of fungus-contaminated vials of steroids, former co-president and co-owner Barry Cadden wrote a series of emails to his staff telling them to stop fudging, WickedLocal Framingham reports from a trial in a federal courthouse in Boston. “No more fudging. No more BS. We must clean up all of our processes.” He was indicted in 2014 following the 2012 fungal meningitis outbreak that killed 76 people.


Merck is ending a late-stage trial of an Alzheimer’s drug after deciding the drug would not work, the latest in a string of disappointing efforts to combat the disease, STAT reports. The study, which was due to be completed mid-year, was testing whether the drug slowed a decline in cognition and daily functioning compared with a placebo. Wall Street had given the drug low odds. This comes three months after Eli Lilly ended a trial of an Alzheimer’s drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!